Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine.

Bouillon R, Van Schoor NM, Gielen E, Boonen S, Mathieu C, Vanderschueren D, Lips P.

J Clin Endocrinol Metab. 2013 Aug;98(8):E1283-304. doi: 10.1210/jc.2013-1195.

PMID:
23922354
2.

Vitamin D supplementation in young White and African American women.

Gallagher JC, Jindal PS, Smith LM.

J Bone Miner Res. 2014 Jan;29(1):173-81. doi: 10.1002/jbmr.2010.

4.

[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].

Lorenzo Sellares V, Torregrosa V.

Nefrologia. 2008;28 Suppl 3:67-78. Spanish.

6.

Relationship between 25-hydroxyvitamin D concentrations, serum calcium, and parathyroid hormone in apparently healthy Syrian people.

Sayed-Hassan R, Abazid N, Alourfi Z.

Arch Osteoporos. 2014;9:176. doi: 10.1007/s11657-014-0176-1. Epub 2014 Apr 9.

PMID:
24715441
7.

The effect of high-dose vitamin D supplementation on calciotropic hormones and bone mineral density in obese subjects with low levels of circulating 25-hydroxyvitamin d: results from a randomized controlled study.

Wamberg L, Pedersen SB, Richelsen B, Rejnmark L.

Calcif Tissue Int. 2013 Jul;93(1):69-77. doi: 10.1007/s00223-013-9729-3. Epub 2013 Apr 17.

PMID:
23591713
8.

Vitamin D does not increase calcium absorption in young women: a randomized clinical trial.

Gallagher JC, Jindal PS, Smith LM.

J Bone Miner Res. 2014;29(5):1081-7. doi: 10.1002/jbmr.2121.

9.

The effect of vitamin D on calcium absorption in older women.

Gallagher JC, Yalamanchili V, Smith LM.

J Clin Endocrinol Metab. 2012 Oct;97(10):3550-6. doi: 10.1210/jc.2012-2020. Epub 2012 Aug 1.

10.

Influence of vitamin D status on vertebral fractures, bone mineral density, and bone turnover markers in normocalcemic postmenopausal women with high parathyroid hormone levels.

Hernández JL, Olmos JM, Pariente E, Nan D, Martínez J, Llorca J, Valero C, Obregón E, González-Macías J.

J Clin Endocrinol Metab. 2013 Apr;98(4):1711-7. doi: 10.1210/jc.2012-3931. Epub 2013 Mar 1.

PMID:
23457409
11.

Serum Parathyroid Hormone Responses to Vitamin D Supplementation in Overweight/Obese Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Lotito A, Teramoto M, Cheung M, Becker K, Sukumar D.

Nutrients. 2017 Mar 6;9(3). pii: E241. doi: 10.3390/nu9030241. Review.

12.

Circulating 25OHD, dietary vitamin D, PTH, and calcium associations with incident cardiovascular disease and mortality: the MIDSPAN Family Study.

Welsh P, Doolin O, McConnachie A, Boulton E, McNeil G, Macdonald H, Hardcastle A, Hart C, Upton M, Watt G, Sattar N.

J Clin Endocrinol Metab. 2012 Dec;97(12):4578-87. doi: 10.1210/jc.2012-2272. Epub 2012 Oct 15.

PMID:
23071162
13.
14.

Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women.

Mastaglia SR, Mautalen CA, Parisi MS, Oliveri B.

Eur J Clin Nutr. 2006 May;60(5):681-7.

PMID:
16391587
15.

Relationship between vitamin D, parathyroid hormone, and bone health.

Sai AJ, Walters RW, Fang X, Gallagher JC.

J Clin Endocrinol Metab. 2011 Mar;96(3):E436-46. doi: 10.1210/jc.2010-1886. Epub 2010 Dec 15.

16.

Effects of postmenopausal hormone replacement therapy with and without vitamin D3 on circulating levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D.

Heikkinen A, Parviainen MT, Tuppurainen MT, Niskanen L, Komulainen MH, Saarikoski S.

Calcif Tissue Int. 1998 Jan;62(1):26-30.

PMID:
9405729
17.

Interpretation of plasma PTH concentrations according to 25OHD status, gender, age, weight status, and calcium intake: importance of the reference values.

Touvier M, Deschasaux M, Montourcy M, Sutton A, Charnaux N, Kesse-Guyot E, Fezeu LK, Latino-Martel P, Druesne-Pecollo N, Malvy D, Galan P, Hercberg S, Ezzedine K, Souberbielle JC.

J Clin Endocrinol Metab. 2014 Apr;99(4):1196-203. doi: 10.1210/jc.2013-3349. Epub 2014 Feb 14.

PMID:
24527713
18.

A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.

Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D, Nickelsen T.

J Clin Endocrinol Metab. 2001 Mar;86(3):1212-21. Erratum in: J Clin Endocrinol Metab 2001 Jul;86(7):3008.

PMID:
11238511
19.

Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.

Recker R, Lips P, Felsenberg D, Lippuner K, Benhamou L, Hawkins F, Delmas PD, Rosen C, Emkey R, Salzmann G, He W, Santora AC.

Curr Med Res Opin. 2006 Sep;22(9):1745-55.

PMID:
16968578
20.

Effects of three-monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility, and muscle strength in older postmenopausal women: a randomized controlled trial.

Glendenning P, Zhu K, Inderjeeth C, Howat P, Lewis JR, Prince RL.

J Bone Miner Res. 2012 Jan;27(1):170-6. doi: 10.1002/jbmr.524.

Supplemental Content

Support Center